18 October 2019 - Amgen and UCB today announced that following a re-examination procedure, the CHMP of the EMA has adopted a positive opinion recommending marketing authorisation for Evenity (romosozumab) for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture and with no history of myocardial infarction or stroke.
Evenity is a novel bone-builder with a dual effect that increases bone formation and to a lesser extent reduces bone resorption (or bone loss).